Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Aquestive Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode.
Aquestive Therapeutics Inc. (AQST)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 3,924,000 | $7,926,480 | -19% | 0.1% |
| 2. | Bracebridge Capital Nancy Zimmerman And Gabriel Sunshine | 428,571 | $865,713 | 0.18% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 288,884 | $583,545 | -8% | 0% |
| 4. | Citadel Investment Group Ken Griffin | 167,817 | $338,990 | +6104% | 0% |
| 5. | Millennium Management Israel Englander | 130,483 | $263,576 | -33% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.81 | 5,000 | Officer | 59,532 | 2022-06-14 | Filing | |
| $0.96 | 91,743 | Officer | 193,702 | 2022-06-08 | Filing | |
| $0.96 | 45,871 | Officer | 882,871 | 2022-06-08 | Filing | |
| $0.96 | 2,293 | Officer | 54,532 | 2022-06-08 | Filing | |
| $0.96 | 13,761 | Officer | 38,761 | 2022-06-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.00 | 50,000 | 984,476 | 2024-03-15 | Filing | ||
| $5.19 | 25,000 | 1,040,371 | 2024-03-08 | Filing | ||
| $6.75 | 23,460 | 837,000 | 2021-02-10 | Filing | ||
| $6.75 | 11,540 | 860,460 | 2021-02-09 | Filing | ||
| $6.50 | 40,792 | 872,000 | 2021-02-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,810,958 | $19,818,135 | 100% | |
| 2. | 1,889,053 | $3,815,887 | 0% | |
| 3. | 846,167 | $1,709,257 | 0.33% | |
| 4. | 591,608 | $1,195,048 | 4.72% | |
| 5. | 494,902 | $999,926 | 0% |
News See All
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Aquestive Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Aquestive Therapeutics Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Aquestive Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the Aquestive Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At this time, all participants are in a listen only-mode.
Is Aquestive Therapeutics, Inc. (AQST) A Good Stock To Buy?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Should I Buy Aquestive Therapeutics, Inc. (AQST)?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Hedge Funds Aren't Crazy About Aquestive Therapeutics, Inc. (AQST) Anymore
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Did Hedge Funds Drop The Ball On Aquestive Therapeutics, Inc. (AQST) ?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before last year's Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads...